News
PAVM
9.33
+1.86%
0.17
Lucid Diagnostics files Form 3 for Chief Medical Officer Victoria Tou-ho Lee
PUBT · 2d ago
PAVmed files Form 3 for Chief Medical Officer Victoria Tou-ho Lee
PUBT · 2d ago
Weekly Report: what happened at PAVM last week (0406-0410)?
Weekly Report · 2d ago
PAVmed Is Maintained at Buy by Ascendiant Capital
Dow Jones · 5d ago
PAVmed Price Target Cut to $65.00/Share From $510.00 by Ascendiant Capital
Dow Jones · 5d ago
PAVmed unit Lucid Diagnostics to join Needham Virtual Healthcare Conference fireside chat
Reuters · 6d ago
Lucid Diagnostics CEO to join Needham Virtual Healthcare Conference fireside chat
Reuters · 6d ago
PAVmed files Form 3 initial beneficial ownership statement for Tasso Partners LLC
Reuters · 04/07 01:46
Weekly Report: what happened at PAVM last week (0330-0403)?
Weekly Report · 04/06 09:56
*PAVmed: Virgilio to Serve as CEO of Subsidiaries PortIO Inc, Octeris Inc >PAVM
Dow Jones · 04/02 12:08
PAVmed names Joseph Virgilio SVP, chief business officer for medical devices
Reuters · 04/02 12:07
*PAVmed: Octeris, Inc. Subsidiary Formed to Advance Endoscopic Esophageal Imaging Tech Recently Licensed From Duke University >PAVM
Dow Jones · 04/02 12:07
PAVmed price target lowered to $16 from $60 at Maxim
TipRanks · 03/31 13:28
PAVmed Reports 2025 Results, Strengthens Balance Sheet
TipRanks · 03/30 13:11
PAVmed FY25 net loss narrows to $3.8 million; revenue falls to $0.1 million
Reuters · 03/30 12:12
PAVmed Non-GAAP EPS of -$1.05
Seeking Alpha · 03/30 12:11
PAVMED INC - Q4 2025 NON-GAAP ADJ LOSS $0.9 MLN, $1.05 PER SHARE
Reuters · 03/30 12:07
Earnings Scheduled For March 30, 2026
Benzinga · 03/30 11:11
Weekly Report: what happened at PAVM last week (0323-0327)?
Weekly Report · 03/30 09:57
Here are the major earnings before the open Monday
Seeking Alpha · 03/29 22:00
More
Webull provides a variety of real-time PAVM stock news. You can receive the latest news about Pavmed through multiple platforms. This information may help you make smarter investment decisions.
About PAVM
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.